Search

USPTO Patent Grant for Viral Infection Compounds Targeting Sigma Receptors

The USPTO has granted a patent (US12582619B2) to Thomas Jefferson University for compounds that modulate Sigma receptors to treat viral infections. The patent covers methods for preventing, treating, or ameliorating viral infections using these compounds, potentially in combination with other therapeutic agents.

USPTO Grants Patent for Sodium Oxybate to Treat Idiopathic Hypersomnia

The United States Patent and Trademark Office (USPTO) has granted patent US12582622B2 to Jazz Pharmaceuticals Ireland Limited for methods of treating idiopathic hypersomnia with sodium oxybate. The patent is effective March 24, 2026.

USPTO Patent Grant: Peptides for Treating Glioma Tumors

The USPTO has granted patent US12582695B2 for peptides, compositions, and methods to treat glioma tumors infiltrated with macrophages. The patent was filed on November 27, 2019, and is assigned to Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk.

USPTO Grants Patent for Compounds Inhibiting Protozoan Parasites

The USPTO has granted a patent (US12582694B2) to the University of South Florida for compounds and methods designed to block protozoan parasite invasion and liver-stage development, specifically mentioning Plasmodium falciparum. This patent covers novel therapeutic approaches for treating parasitic infections.

USPTO Patent Granted for Cognitive Disorder Treatment Compound

The USPTO has granted patent US12583884B2 to AELIS FARMA for a compound, 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one, for use in treating cognitive disorders. The patent filing date was December 18, 2019.

USPTO Patent for Hair Follicle Regeneration

The USPTO has granted Washington University a patent (US12582649B2) for compositions and methods for hair follicle regeneration using TRPV4 activating agents. The patent aims to treat hair loss conditions such as alopecia and telogen effluvium.

USPTO Patent Grant: Tumor Treatment with Antibodies

The USPTO has granted patent US12582713B2 to Bristol-Myers Squibb Company for methods of treating tumors using pharmaceutical compositions containing anti-PD-1 or anti-PD-L1 antibodies, particularly for subcutaneous delivery. The patent also covers compositions that include an endoglycosidase hydrolase enzyme.

USPTO Grants Patent for Flavivirus Cross Neutralizing Antibody

The USPTO has granted patent US12583912B2 for a flavivirus cross-neutralizing antibody developed by the Japan Institute for Health Security. This antibody specifically targets the E protein of flaviviruses, including Zika, dengue, and Japanese encephalitis viruses, and aims to control infection with suppressed Antibody-Dependent Enhancement (ADE).

USPTO Patent for Alzheimer's Treatment Using LRP1/SorLA Antagonist

The USPTO has granted a patent (US12583920B2) to the University of Maryland, Baltimore, for methods and compositions to treat or prevent Alzheimer's disease using LRP1 and/or SorLA antagonists. The patent covers specific therapeutic approaches targeting tau internalization and trafficking in neuronal cells.

USPTO Patent Grant US12582691B2: Yunnan Baiyao/Xingnaojing for TBI

The USPTO has granted patent US12582691B2 to Lotus Biotech.com LLC for methods of administering Yunnan Baiyao or Xingnaojing to patients with moderate-to-severe traumatic brain injury (TBI) and craniotomy. The patent covers methods for improving postoperative recovery and inhibiting adverse impacts associated with TBI and related neurological conditions.

USPTO Patent Grant: Cancer Treatment Compositions

The USPTO has granted a patent (US12582690B2) to the Korea Institute of Science and Technology for compositions containing Rubus longisepalus var. tozawai extracts for preventing or treating cancer. The patent details specific anticancer efficacy against various cancers, including diffuse-type gastric cancer.

Patent for Crohn's Disease Indicator and Treatment

The USPTO has granted Washington University a patent (US12582696B2) for methods to treat, select, and monitor inflammatory bowel disease using Debaryomyces species as a biomarker. The treatment involves administering an antifungal compound and detecting fungal DNA or antibodies.

USPTO Patent Granted for Cancer Treatment with ERK Inhibitors

The USPTO has granted a patent (US12582635B2) to Biomed Valley Discoveries, Inc. for methods of treating cancer with atypical BRAF mutations using ERK inhibitors. The patent covers compositions, methods for treatment, and identification of suitable patient populations.

USPTO Patent Grant for CAH Treatment Compound

The USPTO has granted patent US12582634B2 to Neurocrine Biosciences, Inc. for a compound and synthetic methods for treating congenital adrenal hyperplasia (CAH). The patent covers specific chemical structures and their preparation, aiming to provide new therapeutic options for this condition.

USPTO Patent Grant for Improving Kidney Function

The USPTO has granted patent US12582631B2 to Chinook Therapeutics, Inc. for methods of improving kidney function. The patent, which includes 36 claims, was filed on August 16, 2022, and granted on March 24, 2026.

USPTO Patent Grant: Dopamine D3 Agonists for CNS Disorders

The USPTO has granted patent US12582648B2 to Bioprojet Pharma for a method of treating central nervous system disorders, including restless leg syndrome and neurodegenerative diseases, using dopamine D3 partial agonists. The patent details specific applications and classifications related to these therapeutic uses.

USPTO Patent US12582642B2 for Treating Bovine Papillomatosis

The USPTO has granted patent US12582642B2 to KINOPHARMA, INC. for a composition and method to treat bovine papillomatosis. The patent covers compounds represented by Formula (I) or their pharmaceutically acceptable salts.

USPTO Grants Patent for Terpenoids in Fibrotic Disease Treatment

The USPTO has granted patent US12582689B2 to ARJIL BIOTECH HOLDING COMPANY LIMITED for a method of treating or preventing fibrotic diseases using terpenoids extracted from Antrodia-camphorate or Anisomeles indica. The patent was granted on March 24, 2026.

USPTO Patent Grant: Composition for Improving Muscle Function

The USPTO has granted patent US12582623B2 to N.V. Nutricia for a composition comprising EPA, MA, and leucine. This composition is intended for the prevention and/or treatment of diseases involving muscle decline or for improving muscle function.

Nestle Patent for MCTs Improving Cognitive Function

The USPTO has granted Nestle a patent (US12582627B2) for MCT formulations designed to improve cognitive functions, such as memory and executive function, and to prevent or treat mild cognitive impairment (MCI). The patent specifies daily dosages and composition ratios of medium chain triglycerides, particularly octanoic acid.

USPTO Patent Grant: Botulinum Toxin for Infertility Treatment

The USPTO has granted a patent (US12582705B2) to CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION for a composition comprising botulinum toxin or a salt thereof. This composition is intended to increase endometrial blood flow and improve implantation potential, potentially treating subfertility or infertility.

USPTO Patent Grant: ARDS Treatment with G-CSF Inhibitors

The USPTO has granted patent US12583929B2 to CSL Innovation Pty Ltd for methods of treating acute respiratory distress syndrome (ARDS) using compounds that inhibit G-CSF signaling. The patent covers compounds and their use in manufacturing medicaments for ARDS prevention and treatment.

USPTO Patent Grant: Bone Fracture Recovery Composition Manufacturing Method

The USPTO has granted a patent (US12582686B2) for a manufacturing method of a composition designed to promote bone fracture recovery. The method involves preparing and processing a specific mixture of herbal and natural ingredients into a liquid extract.

Immunotherapy Patent for H3K27M Mutation Cancers Issued

The USPTO has issued a new patent (US12582675B2) to The Board of Trustees of the Leland Stanford Junior University for methods of treating cancers harboring an H3K27M mutation using immunotherapy. The patent details the use of immune cells engineered to express GD2-specific chimeric antigen receptors.

USPTO Patent Grant: Allergy Treatment Compositions

The USPTO has granted patent US12582679B2 to Vedanta Biosciences, Inc. for compositions and methods for treating allergy, including food allergy. The patent covers novel approaches to modulating immune responses and inducing immune tolerance or desensitization.

Vanadium Compounds Patented for Cancer Treatment

The USPTO has granted a patent (US12582672B2) to The Broad Institute, Inc. for vanadium compositions and methods for treating cancers, particularly those expressing elevated levels of SLC26A2. The patent covers the use of bis(maltolato)oxovanadium(IV) (BMOV) and related compounds.

USPTO Patent Grant for API Crystalline Form Preparation

The USPTO has granted patent US12583860B2 to Apotex Inc. for processes to prepare multicomponent crystalline forms of active pharmaceutical ingredients using solvent vapour. The patent covers methods involving mixing a solid API with a liquid or solid pharmaceutically acceptable entity in the presence of solvent vapour, utilizing standard rotary apparatus.

USPTO Patent Grant: Crystal Form of Nitroxoline Prodrug

The USPTO has granted patent US12583835B2 for a crystal form of a nitroxoline prodrug, a pharmaceutical composition containing it, and its preparation and application. The patent, assigned to Jiangsu Yahong Meditech Co., Ltd., describes crystal forms A and B with improved properties for industrial production and drug efficacy compared to nitroxoline.

USPTO Patent for Acetic Acid Derivatives as Safeners

The USPTO has granted a patent (US12583826B2) to Bayer Aktiengesellschaft for acetic acid derivatives and salts thereof, intended for use as safeners in crop protection compositions. These compounds aim to reduce the phytotoxic effects of agrochemicals, particularly herbicides.

USPTO Grants Patent for Nanoporous Material for Ion Channels

The USPTO has granted a new patent (US12583863B2) to the University of Wyoming for a synthetically modifiable ion channel material. This material, a nanoporous structure with controlled electronic and ion transport properties, mimics natural zeolites and MOFs.

Organic EL Device with Different Host Materials

The USPTO has granted a patent for an organic electroluminescent (EL) device. The patent describes a device with two emitting layers, each containing a different host material and a compound that emits fluorescence with a main peak wavelength of 500 nm or less. The patent specifies a condition for the triplet energy of the host materials.

USPTO Patent US12583828B2: Aromatic Carbonyl Compounds Preparation Process

The USPTO has granted patent US12583828B2 to BASF SE for a process to prepare aromatic carbonyl compounds. The patent describes a catalytic oxidation method using molecular oxygen, a cobalt(II) salt, and N,N′,N″-trihydroxyisocyanuric acid (THICA).

USPTO Patent Grant: Oxetane Derivative Synthesis Method by Microreactor

The USPTO has granted a patent (US12583830B2) for a microreactor-based synthesis method for oxetane derivatives. The patent, assigned to Changzhou Tronly Advanced Electronic Materials Co., Ltd., details a process that improves efficiency, yield, and safety compared to traditional methods.

Biologically Active Taxane Analogs and Oral Treatment Methods - Patent Granted

The USPTO has granted a patent (US12583865B2) to Tapestry Pharmaceuticals, Inc. for biologically active taxane analogs and methods of oral treatment for cancer. The patent covers novel chemical compounds, compositions, manufacturing methods, and combinations with other therapeutic agents.

USPTO Patent Grant: IAP Antagonists for Cancer Treatment

The USPTO has granted a patent (US12583866B2) to BeOne Medicines I GmbH for novel pyrido[2,3-b][1,4]oxazine or tetrahydropyrido[2,3-b][1,4]oxazepine derivatives. These compounds act as antagonists of Inhibitors of Apoptosis Proteins (IAPs) and are intended for use in treating cancer by inducing or sensitizing cells to apoptotic cell death.

USPTO Patent Grant: Pyridone Derivative Crystal Form

The USPTO has granted a patent to Jiangxi Caishi Pharmaceutical Technology Co., Ltd. for a novel pyridone derivative crystal form and its preparation method. This patent covers specific crystal forms and their application in treating influenza, potentially offering improved efficacy and bioavailability.

USPTO Patent Grant: JAK Inhibitors Synthesis Methods

The USPTO has granted patent US12583868B2 for novel JAK inhibitors and methods for their synthesis and use, assigned to Galderma Holding SA. The patent covers compounds with formula (I) and their application in treating various diseases.

A2A Receptor Antagonist Salt and Crystal Forms

The USPTO has granted patent US12583869B2 for a salt form and crystal form of an adenosine A2A receptor antagonist, along with its preparation method. The patent, assigned to CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD., also covers the application of these forms in preparing medicine for A2A receptor-related diseases.

USPTO Patent Grant: Diastereomer-Enriched Odorant Mixture Preparation

The USPTO has granted patent US12583833B2 to Symrise AG for a distillative process to prepare a diastereomer-enriched odorant mixture. The patent covers the process, the enriched mixture, and its use in perfumery to impart or enhance floral odor notes.

USPTO Patent Grant US12583859B2 for PRMT5 Inhibitors

The USPTO has granted patent US12583859B2 to the California Institute of Technology for PRMT5 inhibitors. The patent covers compounds and methods useful in treating cancers and other diseases.

USPTO Patent Grant: PSMA Imaging Agents

The United States Patent and Trademark Office (USPTO) has granted patent US12583887B2 to Siemens Medical Solutions USA, Inc. for PSMA imaging agents. The patent covers compounds and methods for imaging prostate-specific membrane antigen (PSMA), suitable for PET and SPECT imaging.

Azaheteroaryl Compound Patent Granted

The USPTO has granted patent US12583870B2 to SHANGHAI BLUERAY BIOPHARMA CO., LTD. for an azaheteroaryl compound and its preparation method. This patent covers compounds and compositions for treating diseases related to EED protein and PRC2 protein complex mechanisms.

USPTO Grants PRMT5 Inhibitors Patent to Merck Sharp & Dohme

The USPTO has granted a new patent (US12583871B2) to Merck Sharp & Dohme LLC for PRMT5 inhibitors. The patent covers compounds and methods for treating conditions such as cancer, sickle cell, and hereditary persistence of foetal hemoglobin.

USPTO Patent Grant for PCSK9 Inhibitors

The USPTO has granted a patent (US12584120B2) to AstraZeneca AB for novel PCSK9 inhibitors and methods of use. The patent covers specific heteroaryl compounds that bind the PCSK9 protein, aiming to advance treatments for conditions related to cholesterol regulation.

USPTO Patent Grant: Light-Emitting Element with Long Lifetime

The USPTO has granted a patent (US12588408B2) to Semiconductor Energy Laboratory Co., Ltd. for a novel light-emitting element. The patent describes an element with a long lifetime and high efficiency, utilizing specific organic acceptor and host materials in its electron-transport layers.

USPTO Patent Grant: Bacterial Infection Treatment Compound

The USPTO has granted a patent (US12583834B2) for a compound and pharmaceutical composition designed to treat bacterial infections by inhibiting Mfd activity. The patent was filed on February 19, 2021, and is assigned to INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT.

USPTO Patent Grant: PD-L1 Antagonist Compound

The USPTO has granted a patent (US12583839B2) to ADLAI NORTYE BIOPHARMA CO., LTD. for a PD-L1 antagonist compound and its pharmaceutical composition. The patent covers compounds of Formula (I) and their use in treating immune-related disorders.

USPTO Patent Grant for Insomnia and Depression Compound

The USPTO has granted a patent (US12583841B2) to Breakthrough Pharmaceuticals Inc. for a tetrahydropyrrolocyclic compound and its application in preparing drugs to treat insomnia and depression by targeting the selective orexin-2 receptor. The patent was filed on January 27, 2022, and granted on March 24, 2026.

USPTO Patent US12583838B2 for Kinase Inhibitors

The USPTO has granted patent US12583838B2 to Insilico Medicine Hong Kong Limited for kinase inhibitors designed for disease treatment. The patent covers specific compounds and their use in pharmaceutical compositions and methods for treating diseases.

USPTO Patent Grant: Daprodustat Crystal Form M Preparation and Use

The USPTO has granted patent US12583823B2 for a specific crystal form (crystal form M) of the drug daprodustat, a proline hydroxylase inhibitor. The patent covers the preparation method and use of this crystal form, which exhibits improved stability and solubility characteristics.